Free Trial

Protagonist Therapeutics (PTGX) Competitors

Protagonist Therapeutics logo
$55.15 +1.41 (+2.62%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$54.98 -0.17 (-0.32%)
As of 07/25/2025 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTGX vs. MRNA, RDY, QGEN, VTRS, ASND, VRNA, BBIO, BPMC, ROIV, and LEGN

Should you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Moderna (MRNA), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

Protagonist Therapeutics vs. Its Competitors

Protagonist Therapeutics (NASDAQ:PTGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Protagonist Therapeutics presently has a consensus price target of $66.10, suggesting a potential upside of 19.85%. Moderna has a consensus price target of $46.11, suggesting a potential upside of 35.03%. Given Moderna's higher probable upside, analysts plainly believe Moderna is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00
Moderna
4 Sell rating(s)
17 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.04

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.9% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Protagonist Therapeutics has a net margin of 27.04% compared to Moderna's net margin of -105.67%. Protagonist Therapeutics' return on equity of 9.22% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics27.04% 9.22% 8.31%
Moderna -105.67%-28.69%-21.94%

Protagonist Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.

Protagonist Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$434.43M7.87$275.19M$0.7573.53
Moderna$3.14B4.21-$3.56B-$8.73-3.91

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Moderna. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 13 mentions for Moderna. Protagonist Therapeutics' average media sentiment score of 0.81 beat Moderna's score of 0.71 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Moderna
7 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Protagonist Therapeutics beats Moderna on 13 of the 16 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTGX vs. The Competition

MetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.33B$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio73.5321.1828.1020.05
Price / Sales7.87288.50432.4490.07
Price / Cash11.9042.7636.2258.56
Price / Book4.878.378.665.87
Net Income$275.19M-$55.19M$3.25B$258.55M
7 Day Performance-0.59%5.88%4.23%3.74%
1 Month Performance-0.13%17.33%10.52%11.75%
1 Year Performance36.92%4.42%34.41%18.03%

Protagonist Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTGX
Protagonist Therapeutics
1.3845 of 5 stars
$55.15
+2.6%
$66.10
+19.9%
+32.7%$3.33B$434.43M73.53120News Coverage
Insider Trade
MRNA
Moderna
4.2995 of 5 stars
$30.97
-0.9%
$46.61
+50.5%
-71.6%$12.09B$3.24B-3.555,800Upcoming Earnings
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7434 of 5 stars
$14.57
+0.6%
$16.95
+16.4%
-9.3%$12.09B$3.81B21.9427,811Earnings Report
QGEN
QIAGEN
3.5861 of 5 stars
$48.06
-0.6%
$49.40
+2.8%
+26.1%$10.75B$1.98B120.495,765Analyst Downgrade
Analyst Revision
VTRS
Viatris
2.4337 of 5 stars
$8.90
+0.2%
$10.40
+16.9%
-20.0%$10.42B$14.74B-2.8132,000
ASND
Ascendis Pharma A/S
3.4327 of 5 stars
$168.02
-1.1%
$223.07
+32.8%
+24.6%$10.39B$393.54M-26.751,017Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.8206 of 5 stars
$104.90
flat
$109.00
+3.9%
+375.4%$8.93B$42.28M-52.4530Positive News
BBIO
BridgeBio Pharma
4.6357 of 5 stars
$45.90
-1.3%
$61.50
+34.0%
+73.4%$8.83B$221.90M-13.00400Analyst Downgrade
BPMC
Blueprint Medicines
1.0836 of 5 stars
$129.46
flat
$128.25
-0.9%
N/A$8.36B$562.12M-52.41640Positive News
Upcoming Earnings
ROIV
Roivant Sciences
2.5987 of 5 stars
$11.48
+0.3%
$16.50
+43.7%
+7.5%$7.78B$29.05M-45.92860News Coverage
Positive News
Insider Trade
LEGN
Legend Biotech
3.7084 of 5 stars
$42.23
+1.5%
$73.33
+73.7%
-26.7%$7.64B$627.24M-71.582,609Positive News

Related Companies and Tools


This page (NASDAQ:PTGX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners